Zamir Butt, Syed Muhammad Ali Shah, Syed Usama Talat, Muhammad Ajmal, Irfan Younis, Muhammad Afzal.
Comparison of sofosbuvir, ribavirin plus peg-interferon-a treatment with sofosbuvir plus ribavirin alone in patients with chronic Hepatitis C.
Isra Med J Jan ;11(6):439-4.

Objective: To compare the efficacy of weekly Peg-interferon-a, weight based ribavirin and sofosbuvir daily for 12 weeks with weight based ribavirin and sofosbuvir daily for 24 weeks in patients with genotype 3a chronic hepatitis C patients. Objective: To compare the efficacy of weekly Peg-interferon-?, weight based ribavirin and sofosbuvir daily for 12 weeks with weight based ribavirin and sofosbuvir daily for 24 weeks in patients with genotype 3a chronic hepatitis C patients. Study Design: Cross-sectional analytical comparative study Study Design: Cross-sectional analytical comparative study Place and Duration: Department of Medicine,Aziz Bhatti Shaheed Teaching Hospital Gujrat from November 2015 to July 2017 Place and Duration: Department of Medicine,Aziz Bhatti Shaheed Teaching Hospital Gujrat from November 2015 to July 2017 Methodology: Patients with chronic hepatitis C genotype 3 infection were divided in two equal groups. Group A included patients treated with Peg-interferon-? weekly, weight based ribavirin and sofosbuvir daily for 12 weeks and group B included patients treated with weight-based ribavirin and sofosbuvir daily for 24 weeks. Methodology: Patients with chronic hepatitis C genotype 3 infection were divided in two equal groups. Group A included patients treated with Peg-interferon-? weekly, weight based ribavirin and sofosbuvir daily for 12 weeks and group B included patients treated with weight-based ribavirin and sofosbuvir daily for 24 weeks. Results: Each group contained 107(N) patients. Mean age in group A was 42.22+10.66 years compared to 49.66+10.51 years in group B. Early virological response (EVR) was achieved by 98.13% patients in group A compared to 97.2% in group B. End treatment response (ETR) rates were similar in both groups as EVR rates. Sustained virological response at 24 weeks (SVR24) was achieved by 94% patients in group A compared to 90% in group B. Binary logistic regression analysis showed no association of treatment history and presence of cirrhosis with either of EVR, ETR or SVR24 (p>0.05). Significant difference in treatment response with either regimen was not noted. Results: Each group contained 107(N) patients. Mean age in group A was 42.22+10.66 years compared to 49.66+10.51 years in group B. Early virological response (EVR) was achieved by 98.13% patients in group A compared to 97.2% in group B. End treatment response (ETR) rates were similar in both groups as EVR rates. Sustained virological response at 24 weeks (SVR24) was achieved by 94% patients in group A compared to 90% in group B. Binary logistic regression analysis showed no association of treatment history and presence of cirrhosis with either of EVR, ETR or SVR24 (p>0.05). Significant difference in treatment response with either regimen was not noted. Conclusion: Dual and triple therapy regimens are equally effective in treating chronic hepatitis C genotype 3 patients. Conclusion: Dual and triple therapy regimens are equally effective in treating chronic hepatitis C genotype 3 patients.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com